advertisement

---

Anders F 21

Showing records 1 to 21 | Display all abstracts from Anders F

73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Anders F
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407

---

73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Teister J
Scientific reports 2017; 7: 6260

---

72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Anders F; Teister J
PLoS ONE 2017; 12: e0175451

---

73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Teister J
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407

---

73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Anders F
Scientific reports 2017; 7: 6260

---

72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Liu A
PLoS ONE 2017; 12: e0175451

---

73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Funke S
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407

---

73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Beck S; Funke S
Scientific reports 2017; 7: 6260

---

72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Funke S
PLoS ONE 2017; 12: e0175451

---

73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Pfeiffer N
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407

---

73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
von Pein H
Scientific reports 2017; 7: 6260

---

73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Grus F
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407

---

72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Grus FH
PLoS ONE 2017; 12: e0175451

---

73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Prokosch V
Scientific reports 2017; 7: 6260

---

73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Solon T
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407

---

72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Thanos S
PLoS ONE 2017; 12: e0175451

---

73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Pfeiffer N
Scientific reports 2017; 7: 6260

---

72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
von Pein HD
PLoS ONE 2017; 12: e0175451

---

73128 Proteomic profiling reveals crucial retinal protein alterations in the early phase of an experimental glaucoma model
Prokosch V
Graefe's Archive for Clinical and Experimental Ophthalmology 2017; 255: 1395-1407

---

73546 Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model
Grus F
Scientific reports 2017; 7: 6260

---

72797 Intravitreal injection of β-crystallin B2 improves retinal ganglion cell survival in an experimental animal model of glaucoma
Pfeiffer N; Prokosch V
PLoS ONE 2017; 12: e0175451

---